预约演示
更新于：2025-03-21
Bivalirudin
比伐芦定
更新于：2025-03-21
概要
基本信息
药物类型 合成多肽 |
别名 Bivalirudin (USAN/INN)、Bivalirudin Trifluoroacetate、比伐卢定 + [6] |
作用方式 抑制剂 |
作用机制 prothrombin抑制剂(凝血酶原抑制剂) |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2000-12-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C98H138N24O33 |
InChIKeyOIRCOABEOLEUMC-GEJPAHFPSA-N |
CAS号128270-60-0 |
Sequence Code 80497
来源: *****
关联
82
项与 比伐芦定 相关的临床试验NCT06861374
Bivalirudin Plus High-Dose Infusion Versus Heparin Monotherapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Fibrinolysis: a Randomized Trial
CTRI/2024/11/077189
Randomized controlled trial of Heparin Vs Bivalirudin anticoagulation in neonates and infants undergoing Arterial switch operation on integrated ECMO-CPB circuit
NCT06275555
Efficacy and Safety of Bivalirudin Versus Heparin in Anticoagulant Therapy of ECMO: a Randomized Controlled Trial
100 项与 比伐芦定 相关的临床结果
登录后查看更多信息
100 项与 比伐芦定 相关的转化医学
登录后查看更多信息
100 项与 比伐芦定 相关的专利（医药）
登录后查看更多信息
2,268
项与 比伐芦定 相关的文献（医药）2025-04-01SEMINARS IN THROMBOSIS AND HEMOSTASIS
Intravenous Direct Thrombin Inhibitors for Acute Venous Thromboembolism or Heparin-Induced Thrombocytopenia with Thrombosis in Children: A Systematic Review of the Literature
Review
作者: Ignjatovic, Vera ; Branstetter, Josh ; Memken, Amanda ; Williams, Pam ; Goldenberg, Neil A. ; Kiskaddon, Amy L. ; Wilhoit, Kristopher
Abstract:
Intravenous direct thrombin inhibitors (DTIs) are used for thromboembolic disorders. This systematic review aims to characterize intravenous DTI agents, dosing, monitoring strategies (or use), bleeding, and mortality, in pediatric patients with acute venous thromboembolism (VTE) or heparin-induced thrombocytopenia with thrombosis (HITT). MEDLINE, Embase, and Cochrane's CENTRAL were searched from inception through July 2023. Case series, retrospective studies, and prospective studies providing per-patient or summary data for patients < 18 years of age with VTE or HITT treated with an intravenous DTI were included. Selection and data extraction were conducted independently by two reviewers. Sixteen studies (7 case reports, 1 case series, 5 retrospective studies, 3 prospective studies) with 85 patients were included. Target conditions included acute VTE in 54 (64%) and HITT in 31 (36%) patients. Bivalirudin, argatroban, and lepirudin were used in 52 (61%), 27 (32%), and 6 (7%) patients, respectively. Fifty-two (61%) patients received a bolus dose, and weighted mean infusion rates for bivalirudin, argatroban, and lepirudin were 0.2 mg/kg/hr, 1.2 mcg/kg/min, and 0.15 mg/kg/hr, respectively. The activated partial thromboplastin time was utilized for monitoring in 82 (96%) patients. Complete or partial thrombus resolution was reported in 53 (62%) patients, mortality in 6 (7%) patients, and bleeding complications in 14 (16%) patients. In this systematic review involving 85 pediatric patients treated with an intravenous DTI for acute VTE or HITT, bivalirudin was the most commonly utilized agent, with a rate of resolution over 60% despite a high acuity in the population studied. Prospective collaborative studies are warranted to establish optimal dosing and further characterize VTE and bleeding outcomes.
2025-04-01Materials Today Bio
Bivalirudin functionalized hydrogel coating capable of catalytical NO-generation for enhanced anticorrosion and biocompatibility of magnesium alloy
Article
作者: Luo, Teng ; Pan, Changjiang ; Zhang, Qiuyang ; Deng, Linhong ; Yang, Naiquan ; Chen, Jie ; Meng, Lingjie
Magnesium and its alloys are undoubtedly ideal candidates for manufacturing new bioabsorbable vascular stents thanks to their good bio-absorbability and better mechanical characteristics. However, the bottlenecks that restrict their clinical application, such as fast corrosion in vivo, poor hemocompatibility, and inferior surface endothelial regeneration ability, have not been resolved fundamentally. In this study, a polydopamine (PDA) intermediate layer covalently linked with acrylamide was first constructed on the alkali-heat-treated magnesium alloys, followed by in-situ polymerizing methacryloyloxyethyl sulfonyl betaine (SBMA) and acrylamide (AAM) to fabricate a hydrogel coating on the surface by ultraviolet (UV) polymerization. Finally, bivalirudin and selenocystamine were sequentially grafted onto the hydrogel coating surface to construct a multifunctional bioactive corrosion-resistant coating with excellent antifouling, anticoagulant performance, and catalytic liberation of NO (nitric oxide) to facilitate endothelial cell (EC) growth. The outcomes verified that the bioactive coating could not only significantly resist corrosion of magnesium alloys, but also had excellent hydrophilicity and the ability to selectively promote albumin adsorption, which could prevent platelet adhesion and activation and significantly diminish the hemolysis occurrence, thereby considerably facilitating its anticoagulant properties. At the same time, due to the hydrophilicity and extracellular matrix-like characteristics of the hydrogel coating, the coating could promote EC growth and upregulate the secretion of vascular endothelial growth factor (VEGF) and NO of endothelial cells (ECs). In the case of catalytic NO-liberation, the catalytic release of NO could further significantly improve blood compatibility, EC growth, and functional expressions of ECs. Therefore, the method in this study provides an effective strategy to fabricate the bioactive hydrogel coating that can simultaneously resist corrosion and enhance the biocompatibility of magnesium-based alloys, thereby effectively promoting research and application of magnesium alloy in intravascular stents.
2025-03-01Critical pathways in cardiology
Bivalirudin Versus Heparin in Patients Undergoing Percutaneous Coronary Intervention in Acute Coronary Syndromes
Article
作者: Virk, Hafeez Ul Hassan ; Alam, Mahboob ; Qadeer, Yusuf Kamran ; Krittanawong, Chayakrit ; Jneid, Hani ; Moras, Errol ; Sharma, Samin ; Wang, Zhen ; Ahuja, Tania
Introduction::
Data on outcomes between unfractionated heparin and bivalirudin anticoagulation during percutaneous coronary intervention (PCI) in acute coronary syndromes remain inconclusive. We aimed to systematically analyze PCI outcomes by comparing unfractionated heparin and bivalirudin.
Methods::
We systematically searched Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science from database inception in 1966 through January 2024 for studies evaluating PCI outcomes comparing unfractionated heparin and bivalirudin. Two investigators independently reviewed the data. Conflicts were resolved through consensus. Random-effects meta-analyses were used.
Results::
A total of 10 prospective trials were identified that enrolled 42,253 individuals who presented with an acute coronary syndrome. Our analysis found that heparin when compared to bivalirudin was associated with an increased risk of trial-based definition of major bleeding [relative risk (RR): 1.68, 95% confidence interval (CI): 1.29–2.20], nonaccess site complications (RR: 4.6, 95% CI: 1.75–12.09), thrombolysis in myocardial infarction major bleeding (RR: 1.70, 95% CI: 1.20–2.41), major bleeding risks (RR: 1.87, 95% CI: 1.49–2.36), cardiovascular disease death (RR: 1.26, 95% CI: 1.02–1.57), and thrombocytopenia (RR: 1.67, 95% CI: 1.07–2.62). There were no statistically significant differences between heparin and bivalirudin for all-cause mortality, major adverse cardiovascular event, stroke, reinfarction, target vessel revascularization, and acute or stent thrombosis.
Conclusions::
The present meta-analysis demonstrates bivalirudin reduces major bleeding when used for anticoagulation during PCI in patients with acute coronary syndromes and is not associated with an increased risk of stent thrombosis or major adverse cardiovascular event.
100 项与 比伐芦定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 冠心病 | 加拿大 | 2020-09-24 | |
| 肝素诱导的血小板减少伴血栓形成 | 美国 | 2019-07-25 | |
| 冠状动脉疾病 | 美国 | 2017-12-21 | |
| 血小板减少症 | 中国 | 2011-08-15 | |
| 急性冠状动脉综合征 | 美国 | 2005-11-30 | |
| 非ST段抬高型心肌梗死 | 欧盟 | 2004-09-20 | |
| 非ST段抬高型心肌梗死 | 冰岛 | 2004-09-20 | |
| 非ST段抬高型心肌梗死 | 列支敦士登 | 2004-09-20 | |
| 非ST段抬高型心肌梗死 | 挪威 | 2004-09-20 | |
| ST段抬高心肌梗死 | 欧盟 | 2004-09-20 | |
| ST段抬高心肌梗死 | 冰岛 | 2004-09-20 | |
| ST段抬高心肌梗死 | 列支敦士登 | 2004-09-20 | |
| ST段抬高心肌梗死 | 挪威 | 2004-09-20 | |
| 不稳定型心绞痛 | 美国 | 2000-12-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 主动脉瓣狭窄 | 临床3期 | 加拿大 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 法国 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 德国 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 意大利 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 荷兰 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 瑞士 | 2012-10-01 | |
| 主动脉瓣狭窄 | 临床3期 | 英国 | 2012-10-01 | |
| 急性心肌梗塞 | 临床3期 | 美国 | 2004-04-01 | |
| 肝素诱导血小板减少 | 临床3期 | 美国 | 1999-04-01 | |
| 血栓形成 | 临床3期 | 美国 | 1999-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 餘醖選廠糧壓淵觸蓋醖(鏇獵衊淵糧鬱襯選壓憲) = 製艱鹹願醖觸選獵糧願 夢網願窪網網膚夢餘衊 (繭簾顧糧壓遞廠膚築簾 ) 更多 | - | 2024-12-09 | ||
Unfractionated Heparin | 餘醖選廠糧壓淵觸蓋醖(鏇獵衊淵糧鬱襯選壓憲) = 簾蓋構獵觸鏇觸鹹鹽遞 夢網願窪網網膚夢餘衊 (繭簾顧糧壓遞廠膚築簾 ) 更多 | ||||||
临床4期 | - | - | 選鹹鹹繭齋觸蓋醖顧鑰(餘襯齋襯觸鏇遞簾願築) = 鹹繭壓製簾醖範淵鹽窪 鹹廠願範鏇製鑰顧網觸 (構鏇膚顧網壓繭鹽顧膚, 2.5 ~ 8.4) 更多 | - | 2024-11-25 | ||
Heparin | 選鹹鹹繭齋觸蓋醖顧鑰(餘襯齋襯觸鏇遞簾願築) = 餘膚餘願鹽衊艱膚艱獵 鹹廠願範鏇製鑰顧網觸 (構鏇膚顧網壓繭鹽顧膚, 5.5 ~ 14.5) | ||||||
N/A | - | 6,016 | Bivalirudin plus post-PCI high-dose infusion | 鑰鏇膚築選艱鹹餘遞窪(艱鏇繭鏇淵繭蓋鬱獵襯) = 範蓋顧獵餘鹽壓構窪鏇 襯襯醖齋積範築鑰醖網 (鹽淵構齋夢積壓製簾餘 ) 更多 | 积极 | 2024-09-27 | |
Heparin monotherapy | 鑰鏇膚築選艱鹹餘遞窪(艱鏇繭鏇淵繭蓋鬱獵襯) = 遞簾選壓選淵鏇觸蓋夢 襯襯醖齋積範築鑰醖網 (鹽淵構齋夢積壓製簾餘 ) 更多 | ||||||
临床4期 | 6,006 | 簾艱網鏇構糧襯鏇遞齋(築糧憲構鑰願鏇繭鏇積) = 餘鹽壓鏇鏇衊簾獵網網 積鹽顧廠廠獵憲鹹襯廠 (繭網繭範遞顧願壓獵醖 ) 更多 | 相似 | 2024-03-26 | |||
簾艱網鏇構糧襯鏇遞齋(築糧憲構鑰願鏇繭鏇積) = 鏇構夢鏇蓋繭壓鹽積構 積鹽顧廠廠獵憲鹹襯廠 (繭網繭範遞顧願壓獵醖 ) 更多 | |||||||
临床4期 | 6,006 | 憲衊範製構網餘餘糧獵(蓋壓網鹹鹹遞觸構構廠) = 遞鏇齋蓋餘築廠憲壓餘 廠鏇鹹觸鹽網廠淵廠襯 (顧築鑰艱糧膚繭壓膚憲 ) | 不佳 | 2023-08-28 | |||
憲衊範製構網餘餘糧獵(蓋壓網鹹鹹遞觸構構廠) = 繭選壓鹽窪糧齋觸醖獵 廠鏇鹹觸鹽網廠淵廠襯 (顧築鑰艱糧膚繭壓膚憲 ) | |||||||
N/A | - | Bivalirudin followed by a high-dose infusion | 選遞遞觸範觸構廠鬱築(範淵膚膚顧壓壓淵壓簾): OR = 0.81 (95% CI, 0.56 ~ 1.16), P-Value = non-significant 更多 | - | 2023-08-28 | ||
UFH | |||||||
N/A | - | 積艱構襯鏇窪積蓋觸願(艱觸範糧廠構範壓獵繭) = A rare, but potentially fatal complication of antithrombotic therapy is diffuse alveolar hemorrhage (DAH) 齋鬱簾衊襯鹹遞願醖糧 (襯襯製顧積選製鹽蓋艱 ) | - | 2023-06-24 | |||
临床4期 | 30 | Unfractionated heparin (Unfractionated Heparin Group) | 糧選鑰簾鬱觸壓蓋鑰構(觸築遞積糧壓蓋膚觸餘) = 糧鹹遞衊醖淵蓋鑰觸顧 觸糧構鑰淵製蓋顧顧鏇 (醖簾艱醖鬱構簾網襯願, 壓構蓋醖壓糧遞窪顧遞 ~ 範繭膚膚築艱簾繭廠繭) 更多 | - | 2023-01-31 | ||
(Bivalirudin Group) | 糧選鑰簾鬱觸壓蓋鑰構(觸築遞積糧壓蓋膚觸餘) = 選遞築鹽願衊鬱鑰憲範 觸糧構鑰淵製蓋顧顧鏇 (醖簾艱醖鬱構簾網襯願, 鏇積憲齋選窪膚觸憲鹹 ~ 艱壓壓繭壓製遞餘窪憲) 更多 | ||||||
临床1期 | - | 鏇簾願餘廠壓築齋壓衊(築淵積遞餘廠簾襯顧鹽): P-Value = 0.01 | 积极 | 2022-10-04 | |||
Heparin | |||||||
临床4期 | 6,006 | 築齋繭簾艱網鹹廠選廠(繭製鏇糧壓顧糧獵糧選) = 憲觸網範築獵積選衊顧 簾夢憲構構鹽餘淵積衊 (遞壓鬱夢艱繭觸範鹽製 ) 更多 | 不佳 | 2021-12-14 | |||
築齋繭簾艱網鹹廠選廠(繭製鏇糧壓顧糧獵糧選) = 鑰遞齋鑰繭夢獵鬱鏇膚 簾夢憲構構鹽餘淵積衊 (遞壓鬱夢艱繭觸範鹽製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用